Compare · LYRA vs MDLN
LYRA vs MDLN
Side-by-side comparison of Lyra Therapeutics Inc. (LYRA) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LYRA and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN carries a market cap of $48.72B.
- MDLN has hit the wire 24 times in the past 4 weeks while LYRA has been quiet.
- MDLN has more recent analyst coverage (25 ratings vs 7 for LYRA).
- Company
- Lyra Therapeutics Inc.
- Medline Inc.
- Price
- -
- -
- Market cap
- -
- $48.72B
- 1M return
- -
- +6.28%
- 1Y return
- -
- -9.03%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2025
- News (4w)
- 0
- 24
- Recent ratings
- 7
- 25
Lyra Therapeutics Inc.
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Latest LYRA
- Director Smith W Bradford returned 640 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SEC Form 15-12G filed by Lyra Therapeutics Inc.
- SEC Form 25 filed by Lyra Therapeutics Inc.
- SEC Form 8-K filed by Lyra Therapeutics Inc.
- Lyra Therapeutics, Inc. Announces Intention to Voluntarily File Form 25 for Delisting from Nasdaq and Subsequent Deregistration with the SEC
- SEC Form 8-K filed by Lyra Therapeutics Inc.
- SEC Form 4 filed by Palasis Maria
- SEC Form 4 filed by Cavalier Jason
- SEC Form 10-K filed by Lyra Therapeutics Inc.
- SEC Form EFFECT filed by Lyra Therapeutics Inc.
Latest MDLN
- Large owner Cp Circle Ml Holdco Gp, Llc converted options into 3,709,698 shares and disposed of 3,709,698 units of Class B Common Stock (SEC Form 4)
- Large owner Carlyle Mozart Coinvestment Holdings, L.P. converted options into 3,709,698 shares and disposed of 3,709,698 units of Class B Common Stock (SEC Form 4)
- Large owner Bx Mozart Ml-1 Holdco L.P. converted options into 7,570,214 shares and disposed of 7,570,214 units of Class B Common Stock (SEC Form 4)
- Large owner Tc Group Cayman Investment Holdings, L.P. converted options into 3,709,698 shares and disposed of 3,709,698 units of Class B Common Stock (SEC Form 4)
- Large owner Carlyle Group Inc. converted options into 3,709,698 shares and disposed of 3,709,698 units of Class B Common Stock (SEC Form 4)
- Large owner Hellman & Friedman Capital Partners X (Parallel), L.P. converted options into 12,128,729 shares and disposed of 12,128,729 units of Class B Common Stock (SEC Form 4)
- Large owner Bcp 8 Holdings Mozart Manager L.L.C. converted options into 7,570,214 shares and disposed of 7,570,214 units of Class B Common Stock (SEC Form 4)
- SEC Form 424B4 filed by Medline Inc.
- Medline Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- Medline launches right-sized Ranpak packaging solutions in two key distribution centers